RESEARCH/PRACTICE REPORTS INTRAVENOUS OR INTRAMUSCULAR TEICOPLANIN ONCE DAILY FOR SKINAND SOFr·TISSUEINFECTIONS

ABSTRACf: Teicoplanin is a new glycopeptideantibiotic with potent activityagainst gram-positivebacteria and pharmacokineticsthat allow once daily administration. To study the efficacy and safety of teicoplanin for skin and soft-tissue infections,75 patients received teicoplanin intravenously (38) or intramuscularly(37, of which 16 were outpatients).Of 62 clinicallyevaluable patients,97 percent of teicoplanin iv and 93 percent of teicoplanin im patients were cured or improved.All teicoplanin iv patients and 64 percent of teicoplanin im patientswere cured microbiologicallyat 24-48 hours posttherapy. Persistenceof organisms frequentlywas associated with skin ulcers or abscesscavities and usually had no bearing on clinical outcome. Possibleadverse clinical and laboratory reactionscaused by teicoplani